FDA says Merck's ridaforolimus meets study goal
March 16, 2012 at 08:51 AM EDT
WASHINGTON, March 16 (Reuters) - U.S. health regulators on Friday said Merck & Co Inc's ridaforolimus tablets met their primary research end-point of reducing by 25 percent the risk of progression or death in patients with metastatic bone sarcoma.